Spruce Biosciences, Inc.
SPRB Nasdaq· Pharmaceutical Preparations
Last close · Oct 26, 2026
$43.99
KIRA · Stoqly’s AI analyst, in plain words
- Spruce Biosciences, Inc. had $0.0M of revenue in fiscal 2025, down 100.0% on the year before.
- Spruce Biosciences, Inc. lost $39.0M in fiscal 2025.
- Spruce Biosciences, Inc. has $48.9M more cash than debt.
Market cap
$107M
P/E
—
Revenue
$0.0M
Net income
−$39.0M
Free cash flow
—
Operating margin
—
Spruce Biosciences, Inc. in 30 seconds · fiscal 2025
Are sales growing?
−100.0%
No. Sales fell 100.0% last year.
Does it make a profit?
−$39.0M
No. It lost money last year.
How healthy are the accounts?
4 / 8
Mixed. It passes 4 of 8 health tests.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What Spruce Biosciences, Inc. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Mar 9, 2026
- Legal name
- SPRUCE BIOSCIENCES, INC.
- CIK
- 0001683553
Spruce Biosciences, Inc. · SPRB
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | — | $0.0M | $10.1M | $4.9M | $0.0M |
| Revenue growth | — | — | — | −51.3% | −100.0% |
| Operating margin | — | — | −515.3% | −1,143.4% | — |
| Net income | −$42.3M | −$46.2M | −$47.9M | −$53.0M | −$39.0M |
| Net margin | — | — | −475.0% | −1,079.9% | — |
| Diluted EPS | −$1.81 | −$1.96 | −$1.24 | −$96.40 | −$50.83 |
| Cash | |||||
| Cash from operations | −$35.9M | −$41.7M | −$33.3M | −$56.0M | −$33.3M |
| Capital expenditure | $0.1M | $0.0M | $0.0M | $0.0M | — |
| Free cash flow | −$36.0M | −$41.7M | −$33.3M | −$56.0M | — |
| FCF margin | — | — | −329.9% | −1,139.6% | — |
| Share count change | 289.9% | 0.7% | 63.7% | −98.6% | 39.4% |
| Debt and strength | |||||
| Cash and short-term investments | $89.0M | $79.1M | $96.3M | $38.8M | $48.9M |
| Debt incl. finance leases | $4.9M | $5.6M | $3.7M | $1.8M | $0.0M |
| Shareholders' equity | $111M | $68.5M | $76.5M | $28.8M | $42.5M |
| Current ratio | 10.4x | 6.7x | 4.2x | 2.9x | 5.2x |
| Interest coverage | −121.9x | −112.6x | −107.6x | −182.9x | −405.7x |
| Returns and quality | |||||
| Return on capital | −121.8% | — | — | — | — |
| Return on equity | −32.4% | −51.4% | −66.1% | −100.7% | −109.2% |
| Return on tangible equity | −38.0% | −67.4% | −62.6% | −184.0% | −91.7% |
| Piotroski F-score | 1 | 1 | 4 | 2 | 4 |
| Altman Z'' | 7.1 | 0.2 | −1.7 | −20.3 | −13.0 |
Insiders bought, 12 months
$0.0M
0 insiders
Insiders sold, 12 months
$0.0M
0 insiders
Of sales under plans
—
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Spruce Biosciences, Inc. · SPRB
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $43.99 a share, the company is worth $107M.
Source: SEC EDGAR XBRL filings (CIK 0001683553). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.